# Safety, Pharmacokinetics, and Pharmacodynamics Study of Single Dose of CNTO 3649 in Healthy Adult Men and Multiple Doses of CNTO 3649 in Participants With Type 2 Diabetes Mellitus

> **NCT02224118** · PHASE1 · COMPLETED · sponsor: **Janssen Pharmaceutical K.K.** · enrollment: 64 (actual)

## Conditions studied

- Healthy
- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** CNTO 3649 10 mcg/kg
- **DRUG:** CNT0 3649 30 mcg/kg
- **DRUG:** CNTO 3649 100 mcg/kg
- **DRUG:** CNTO 3649 300 mcg/kg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02224118
- **Lead sponsor:** Janssen Pharmaceutical K.K.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-07
- **Primary completion:** 2010-03
- **Final completion:** 2010-03
- **Target enrollment:** 64 (ACTUAL)
- **Last updated:** 2014-09-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02224118

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02224118, "Safety, Pharmacokinetics, and Pharmacodynamics Study of Single Dose of CNTO 3649 in Healthy Adult Men and Multiple Doses of CNTO 3649 in Participants With Type 2 Diabetes Mellitus". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02224118. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*